1. Adjuvant capecitabine resulted in fewer instances of disease recurrence and death compared to standard therapy.
2. Overall and failure-free survival at 3 years was significantly greater in the capecitabine group.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Nasopharyngeal carcinoma is a form of invasive head and neck cancer with a favorable...